Informativa su Privacy e Cookies
Questo sito utilizza cookie tecnici funzionali, cookie analitici di terze parti anonimizzati, e cookie di terze parti che potrebbero profilare: accedendo a qualunque elemento/area del sito al di fuori di questo banner, acconsenti a ricevere i cookie secondo le tue Preferenze. Puoi liberamente consentire, negare o impostare le tue preferenze sull\'utilizzo dei Cookies tramite i link di seguito. Se vuoi saperne di più puoi consultare la pagina Informazioni su Privacy e Cookies. Ti ricordo che i Cookies saranno registrati sul tuo browser solo a seguito del tuo consenso e secondo la modalità tecniche consentite dai produttori software, puoi liberamente cancellare i Cookies in qualsiasi momento tramite l\'apposita funzione del tuo browser.  Se non consenti l\'utilizzo di alcuni Cookies si potrebbero verificare malfunzionamenti delle pagine web oppure alcuni contenuti potrebbero non funzionare. [user_consent_state] [cookie_audit columns=\"cookie,description\" heading=\"The below list details the cookies used in our website.\"]
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

No cookies to display.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

No cookies to display.

[Corrections] Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4

Di |2024-06-28T00:30:01+02:00Giugno 28th, 2024|Categorie: Coronavirus Lancet|

Chang CC, Harrison TS, Bicanic TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S147...

[Correspondence] Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities

Di |2024-06-21T00:30:01+02:00Giugno 21st, 2024|Categorie: Coronavirus Lancet|

In the 2024 study by Ann R Falsy and colleagues, the Ad26.RSV.preF–RSV preF protein vaccine offered strong protection against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in healthy adults aged 65 years or older (84·1%) and ...

[Corrections] Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4

Di |2024-06-15T00:30:01+02:00Giugno 15th, 2024|Categorie: Coronavirus Lancet|

Dattwyler RJ, Arnaboldi PM. Vaccination hesistancy in Lyme borreliosis. Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4—In this Comment, the declaration of interests has been updated. This correction has b...

[Articles] Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Di |2024-06-14T00:30:06+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5–17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previo...

[Articles] Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Di |2024-06-14T00:30:02+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for ...

[Comment] Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis

Di |2024-06-14T00:30:01+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

Yearly, about 410 000 patients worldwide develop rifampicin-resistant tuberculosis, resistant to the most powerful first-line tuberculosis drug. In 2012, treatment for rifampicin-resistant tuberculosis constituted mainly regimens of 18 months or longer...

[Correspondence] Survival analysis of patients with cholera admitted to treatment centres in Lusaka, Zambia

Di |2024-06-13T00:30:01+02:00Giugno 13th, 2024|Categorie: Coronavirus Lancet|

Cholera remains a global threat to health security, particularly in sub-Saharan Africa where outbreaks have become frequent, with increased magnitude and fatalities.1,2 While the world is preparing for the next pandemic, we explored clinical outcomes a...

Torna in cima